$1450 | Site License
$2750 | Global License

GlaxoSmithKline: Performance, Capabilities, Goals and Strategies in the Global Pharmaceutical Market [Report Updated: 25-07-2017]

Published by Venture Planning Group (VPG): 25 Jul 2017 | 107281 | In Stock

Introduction

The new VPGMarketResearch.com report on GlaxoSmithKline performance, capabilities, goals and strategies provides significant competitor information, analysis and insight critical to the development and implementation of effective marketing and R&D programs.  

In the dynamic and fragmented pharmaceutical market, besieged by intense competition and rapid change of technological innovations, the ability to anticipate new product introductions and marketing strategies is particularly important...and can spell the difference between success and failure.

The report’s objectives include:

- To help current suppliers realistically assess their financial, technological and marketing capabilities vis-à-vis its competitors.

- To assist potential market entrants in evaluating prospective acquisitions and joint venture candidates.

- To complement the organizations’ internal competitor information gathering efforts with strategic analysis, data interpretation and insight.

- To identify least competitive market niches with significant growth potential.

Table of Contents

1. Organization and Management

2. Acquisitions and Divestitures

3. Facilities and Employees

4. Research and Development

5. Technological Know-How

6. Key Products

7. Marketing Capabilities

8. Financial Results

9. Strengths and Weaknesses

10. Strategic Direction

Table of Contents
for GlaxoSmithKline: Performance, Capabilities, Goals and Strategies in the Global Pharmaceutical Market [Report Updated: 25-07-2017]

  • Request Table of Contents reportstore@bioportfolio.com

Additional Details

Publisher

Venture Planning Group (VPG)

Publisher Information

Reference

107281 | VPPH26986

Report Format

PDF

Venture Planning Group (VPG) Reports

Related Reports

TitleDate PublishedPrice fromMore Details
GlaxoSmithKline Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
GlaxoSmithKline K.K. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGlaxoSmithKline K.K. (GSK Japan) a subsidiary of GlaxoSmithKline Plc is a pharmaceutical comp...
10 Mar 2016 by Global Data USD $250 More Info
GlaxoSmithKline Pharmaceuticals Limited (GLAXO) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGlaxoSmithKline Pharmaceuticals Limited (GSK India) is a pharmaceutical company that manufact...
04 Mar 2016 by Global Data USD $250 More Info
GlaxoSmithKline Plc (GSK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
SummaryGlaxoSmithKline plc (GSK) is a healthcare company, which focuses on the development, manufact...
04 Mar 2016 by Global Data USD $250 More Info
GlaxoSmithKline Plc (GSK) - Medical Equipment - Deals and Alliances Profile
SummaryGlaxoSmithKline plc (GSK) is a healthcare company, which focuses on the development, manufact...
24 Feb 2016 by Global Data USD $250 More Info
GlaxoSmithKline Consumer Nigeria PLC (GLAXOSMITH) - Financial and Strategic SWOT Analysis Review
SummaryGlaxoSmithKline Consumer Nigeria PLC (GlaxoSmithKline Consumer Nigeria) a subsidiary of Glaxo...
09 Jan 2016 by Global Data USD $300 More Info
GlaxoSmithKline Consumer Nigeria PLC (GLAXOSMITH) - Financial and Strategic SWOT Analysis Review
SummaryGlaxoSmithKline Consumer Nigeria PLC (GlaxoSmithKline Consumer Nigeria) a subsidiary of Glaxo...
08 Nov 2015 by Global Data USD $300 More Info
Physician Views: Is GlaxoSmithKline's BRAF/MEK combo making headway in V600 mutation-positive melanoma patients?
Scope Although the clinical promise of cancer immunotherapies looks poised to see these products gai...
22 Jul 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Assessing the launch of GlaxoSmithKline's Breo Ellipta
Scope It remains early in the launch, but available evidence suggests that GlaxoSmithKline's Breo El...
21 Jan 2014 by FirstWord Pharma USD $695 More Info
Physician Views: Can GlaxoSmithKline strike early with Anoro? / What role will dosing, inhaler type play in uptake of LAMA/LABA combinations for COPD?
ScopeThis year looks set to be one of notable evolution for the US chronic obstructive pulmonary dis...
01 Aug 2013 by FirstWord Pharma USD $695 More Info

This report is published by Venture Planning Group (VPG)

Download Free Report Summary PDF

GlaxoSmithKline: Performance, Capabilities, Goals and Strategies in the Global Pharmaceutical Market [Report Updated: 25-07-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data